Efinopegdutide
Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist
N/A Amino Acids · MW: N/A
Amino Acids
N/A
Molecular Weight
N/A
Half-life
Approximately 1 week
Research Score
4.2
Studies
14
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Efinopegdutide?
Efinopegdutide is a PEGylated GLP-1/glucagon dual agonist developed for obesity and liver disease. Its design aims to combine appetite suppression with enhanced energy expenditure and hepatic fat reduction.
Key Benefits & Mechanisms
reduced body weight
improved insulin sensitivity
reduced liver fat
greater satiety
Research Summary
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Related Peptides
Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Weight ManagementCotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Weight ManagementMazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight Management